Italian Translation and Validation of the Non-Motor Fluctuation Assessment (NoMoFA) Questionnaire: an Observational, Multicentric, Cross-sectional, 6-months Duration Study on 200 Consecutive Parkinson's Disease Patients.

Launched by A.O.U. CITTÀ DELLA SALUTE E DELLA SCIENZA · May 6, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on translating and validating a questionnaire called the Non-Motor Fluctuation Assessment (NoMoFA) for Italian-speaking patients with Parkinson's disease (PD). Parkinson's disease is not just about movement problems; it can also cause a range of non-motor symptoms like fatigue, sleepiness, and confusion, which can change from day to day. The NoMoFA questionnaire helps doctors understand how severe these non-motor symptoms are, which is important for improving patients' quality of life. By creating an Italian version of this questionnaire, the study aims to ensure that Italian patients can accurately express their experiences and receive better care.

To participate in this study, individuals must have a confirmed diagnosis of idiopathic Parkinson's disease, be Italian speakers, and show signs of fluctuating symptoms. They should also be able to understand the questions and provide informed consent. Participants will be asked to complete the translated questionnaire, which will help researchers confirm that it works well for Italian patients. This is a great opportunity for those who want to have their voices heard in the management of their condition while contributing to improving tools that help assess Parkinson's disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of idiopathic Parkinson\'s disease according to the 2015 Movement Disorders Society (MDS) criteria (Postuma et al. Mov Dis, 2015);
• • Italian speaker;
• • Mini-mental state examinations (MMSE) score \>25;
• • Presence of symptoms fluctuations, as per a Wearing-off questionnaire 19 (WOQ-19) score\>=2;
• • Stable antiparkinsonian medications for at least three months
• • Ability to provide informed consent.
• Exclusion Criteria:
• • Atypical Parkinsonian syndrome
• • H\&Y\>4
• • Patients under legal protection